logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment

Bhatt NB, Barau C, Amin A, Baudin E, Meggi B,  et al.
2014-03-24 • Antimicrobial Agents and Chemotherapy
2014-03-24 • Antimicrobial Agents and Chemotherapy
This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patien...
Journal Article
|
Research

Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial

Atwine D, Baudin E, Gele T, Muyindike WR, Mworozi K,  et al.
2020-01-30 • Journal of Antimicrobial Chemotherapy
2020-01-30 • Journal of Antimicrobial Chemotherapy
Background: High-dose rifampicin is considered to shorten anti-TB treatment duration but its effect on antiretroviral metabolism is unknown.

Objectives: To assess the effect o...
Journal Article
|
Research

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship

Bhatt NB, Baudin E, Meggi B, da Silva C, Barrail-Tran A,  et al.
2014-09-18 • Journal of Antimicrobial Chemotherapy
2014-09-18 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12...